Tipifarnib in the treatment of acute myeloid leukemia.
Farnesyltransferase inhibitors (FTIs) are a new class of biologically active anticancer drugs. The exact anti-tumorigenic mechanism is currently unknown. FTIs inhibit farnesylation of a wide range of target proteins. In preclinical models, tipifarnib (R115777, Zarnestra(R)), a non-peptidomimetic competitive FTI, showed great potency against leukemic cells. Although it has recently demonstrated clinical responses in adults with refractory and relapsed acute myeloid leukemia (AML), and in older adults with newly diagnosed poor-risk AML, its activity was far less than anticipated. However, it appears that tipifarnib as a single agent may be important in selected groups of patients. Much remains to be learned to optimize such therapy in patients with AML. To this end, trials that combine tipifarnib with cytotoxics are ongoing.
Thomas
Xavier
X
Hematology, Edouard Herriot Hospital, Lyon, France.
Elhamri
Mohamed
M
Blood. 2003 Dec 1;102(12):3880-9
12920034
Biochemistry. 1998 May 12;37(19):6924-38
9578579
Cell. 1992 Dec 24;71(7):1143-55
1473150
Cancer Res. 2001 Jan 1;61(1):131-7
11196150
Cancer. 2006 Mar 1;106(5):1090-8
16435386
J Clin Oncol. 2004 Dec 1;22(23):4816-22
15570084
Mol Cell Biol. 1998 Oct;18(10):5699-711
9742087
J Biol Chem. 1997 Apr 11;272(15):10232-9
9092572
Cancer Res. 1994 Jun 15;54(12):3229-32
8205544
Cell Growth Differ. 1992 Jul;3(7):461-9
1419908
Curr Top Med Chem. 2003;3(10):1095-102
12769710
N Engl J Med. 1999 Sep 30;341(14):1051-62
10502596
Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67
10680081
Nature. 1995 Aug 17;376(6541):599-602
7637810
Mol Cancer Ther. 2005 Jun;4(6):918-26
15956249
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15356-61
9860973
J Cell Biol. 1997 Oct 20;139(2):435-47
9334346
Blood. 2007 Feb 15;109(4):1387-94
17082323
Blood. 1999 Mar 15;93(6):2043-56
10068678
Cell. 1992 Aug 7;70(3):389-99
1643657
Cancer Res. 2003 Sep 15;63(18):5656-68
14522880
J Clin Oncol. 1999 Nov;17(11):3631-52
10550163
J Clin Oncol. 2004 Apr 1;22(7):1287-92
15051776
Annu Rev Biochem. 1993;62:851-91
8352603
Blood. 2006 May 1;107(9):3481-5
16455952
Invest New Drugs. 1999;17(3):241-58
10665477
Blood. 1997 Nov 1;90(9):3322-31
9345014
Blood. 2007 Jun 15;109(12):5151-6
17351110
Curr Opin Pharmacol. 2002 Aug;2(4):388-93
12127871
Mol Reprod Dev. 1995 Dec;42(4):459-67
8607977
Anticancer Drugs. 2001 Mar;12(3):193-7
11290865
Blood. 2001 Jun 1;97(11):3361-9
11369625
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12479-84
15308774
Cell Signal. 2004 Oct;16(10):1105-12
15240005
Mol Cell Biol. 2001 Oct;21(20):6906-12
11564874
J Biol Chem. 2002 Nov 29;277(48):46659-68
12235145
Blood. 1997 May 1;89(9):3323-9
9129038
Blood. 2007 May 15;109(10):4158-63
17264294
Science. 1999 Nov 12;286(5443):1358-62
10558990
J Clin Oncol. 2000 Feb;18(4):927-41
10673536
Cancer Res. 1997 Feb 15;57(4):708-13
9044849
Anticancer Drugs. 2005 Mar;16(3):317-21
15711184
Nature. 1993 Dec 16;366(6456):643-54
8259209
Cancer Res. 2005 Apr 15;65(8):3117-25
15833841
Trends Cell Biol. 2000 Mar;10(3):85-8
10675900
J Cell Biol. 1995 Aug;130(3):507-18
7542657
J Biol Chem. 1997 May 30;272(22):14459-64
9162087
Blood. 2003 Dec 15;102(13):4527-34
12947010
J Biol Chem. 2000 Sep 29;275(39):30451-7
10852915
Cancer Res. 1999 Nov 1;59(21):5492-6
10554025
Clin Cancer Res. 2007 Apr 1;13(7):2254-60
17404110
BMC Cancer. 2004 Aug 25;4:56
15329151
J Lipid Res. 2006 Jan;47(1):15-31
16278491
Leukemia. 2000 Mar;14(3):480-7
10720146
Cancer Res. 2004 Nov 15;64(22):8389-96
15548709
Exp Cell Res. 2004 Nov 15;301(1):43-9
15501444
Blood. 2005 Jun 15;105(12):4759-66
15728126
J Biol Chem. 2005 Sep 2;280(35):31101-8
16006564
Cancer Res. 1989 Sep 1;49(17):4682-9
2547513
J Biol Chem. 1997 Jun 20;272(25):15591-4
9188444
Leukemia. 2003 Aug;17(8):1482-98
12886235
J Clin Oncol. 2002 Jun 1;20(11):2726-35
12039935
Cancer Lett. 1996 Dec 20;110(1-2):49-55
9018080